Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2024; 14(1): 525-533


Effects of 5-fluorouracil, thymoquinone and mammary stem cells’ exosomes on in vitro cultured breast cancer cells

Ahmed A. Hassan, Doaa Ibrahim, Ayman A. Saleh, Asmaa T.Y. Kishawy, Reham H.A. Mohamed, Safaa I. Khater.




Abstract
Cited by 0 Articles

Background:
5-FU is an antimetabolic agent used for treating slowly growing solid tumors like breast and ovarian carcinoma. Thymoquinone (TQ) is a main biologically active constituent of Nigella sativa, it has been found to demonstrate anticancerous effects in several preclinical studies, and this is because TQ possesses multi-target nature. Stem cells-derived exosomes are in the spotlight of research and are promising tissue regenerative and anticancer cell-derived nanovesicles.
Aim:
Herein, we studied the antineoplastic effects of Exosomes derived from mammary stem cells (MaSCs-Exo) on breast cancer cells, alone or combined with TQ when compared to a breast cancer chemotherapeutic agent; 5-FU.
Methods:
Our approach included performing viability test and measuring the expression of pro-apoptotic gene (Bax), anti-apoptotic gene (BCL-2) and angiogenic gene (VEGF) on Human MCF-7 cells (breast adenocarcinoma cells), the MCF-7 cells were cultured and incubated with medium containing 5-FU (25 μg/mL), Thymoquinone (200 μg/mL), MaSCs-Exo (100 μg protein equivalent), a combination of TQ (200 μg/mL) and MaSCs-Exo (100 μg).
Results:
Our obtained results show that TQ and MaSCs-Exo each can effectively inhibit breast cancer cell line (MCF-7) proliferation and growth. Also, the results show that the combination of TQ and MaSCs-Exo had higher cytotoxic effects on MCF-7 breast cancer cells than TQ or 5-FU, alone.
Conclusion:
The present study shows promising anticancer potential of exosomes isolated from mammary stem cells; this effect was potentiated by adding thymoquinone with MaSCs-derived exosomes.

Key words: Mammary stem cells, 5-fluorouracil, Apoptosis, Breast cancer, Anti-tumor






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.